Thistle Mary

SEC source: 0001193125-26-276055 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,319

Underlying: Common Stock · 25,319 shares

Expires 2026-06-16

F1 · derivative.exercise_date: The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.

SEC source: 0001193125-26-272690 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,810

Underlying: Common Stock · 9,810 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-310965 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,826

Underlying: Common Stock · 10,826 shares

Expires 2036-06-11

F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.

F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.

F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.

SEC source: 0001689375-26-000036 · wk-form4_1781298072.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2036-06-10

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.

SEC source: 0001193125-25-251986 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,521

Underlying: Common Stock · 53,521 shares

Expires 2035-10-22

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000950170-25-102504 · ownership.xml · derivative · entry 5

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,155 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

SEC source: 0000950170-25-102504 · ownership.xml · derivative · entry 4

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,309 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

SEC source: 0000950170-25-102504 · ownership.xml · derivative · entry 3

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,928 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

SEC source: 0000950170-25-102504 · ownership.xml · derivative · entry 2

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,068 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.

SEC source: 0000950170-25-102504 · ownership.xml · nonDerivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F2 · shares: Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU.

F1 · price: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration").

F2 · price: Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU.

SEC source: 0001689375-25-000032 · wk-form4_1749730041.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 11, 2025 or (ii) the Issuer's next annual meeting of stockholders.

SEC source: 0000950170-25-077267 · ownership.xml · nonDerivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 22, 2026 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000950170-25-028247 · ownership.xml · derivative · entry 2

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-028247 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-24-094861 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,743

Underlying: Common Stock · 25,743 shares

Expires 2034-08-08

F1 · derivative.exercise_date: The option represents a right to purchase a total of 25,743 shares of the Issuer's common stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date.

SEC source: 0001689375-24-000036 · wk-form4_1718397383.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 13, 2024 or (ii) the Issuer's next annual meeting of stockholders.

SEC source: 0000950170-24-070842 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,068

Underlying: Common Stock · 18,068 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option was awarded to the reporting person pursuant to the Issuer's 2021 Stock Option and Incentive Plan. The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 5, 2025 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000950170-24-054698 · ownership.xml · derivative · entry 6

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,928

Underlying: Common Stock · 13,928 shares

Expires 2033-06-07

F3 · derivative.exercise_price: The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability.

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000950170-24-054698 · ownership.xml · derivative · entry 5

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,928 shares

Expires 2033-06-07

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F5 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000950170-24-054698 · ownership.xml · derivative · entry 4

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,155

Underlying: Common Stock · 12,155 shares

Expires 2032-06-09

F3 · derivative.exercise_price: The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability.

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and the shares subject to this stock option award are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-054698 · ownership.xml · derivative · entry 3

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,155 shares

Expires 2032-06-09

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F4 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and the shares subject to this stock option award are fully vested and exercisable as of the date hereof.

SEC source: 0000950170-24-054698 · ownership.xml · derivative · entry 2

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,309

Underlying: Common Stock · 24,309 shares

Expires 2032-04-18

F3 · derivative.exercise_price: The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability.

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment having vested on August 27, 2022.

SEC source: 0000950170-24-054698 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,309 shares

Expires 2032-04-18

F1 · kind: On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the "Effective Date"). Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment having vested on August 27, 2022.

SEC source: 0000950170-24-037382 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,767

Underlying: Common Stock · 12,767 shares

Expires 2034-03-24

F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-23-028396 · ownership.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

SEC source: 0001104659-23-070337 · tm2318445-3_4seq1.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 8, 2023 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.

SEC source: 0000899243-23-015172 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,928

Underlying: Common Stock · 13,928 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-23-014918 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-06-05

F1 · derivative.exercise_date: One-twelfth of the shares underlying the option vest in equal monthly installments measured from June 6, 2023, with the first vesting occurring on July 6, 2023, subject to the Reporting Person's continued service through each such date.

SEC source: 0000899243-22-024011 · doc4.xml · derivative · entry 2

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments beginning on July 13, 2022.

SEC source: 0000899243-22-024011 · doc4.xml · nonDerivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

SEC source: 0000899243-22-023997 · doc4.xml · derivative · entry 2

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-06-21

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments beginning on July 13, 2022.

SEC source: 0000899243-22-023997 · doc4.xml · nonDerivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

SEC source: 0000899243-22-023068 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

SEC source: 0000899243-22-022157 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,155

Underlying: Common Stock · 12,155 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 9, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0001104659-22-068503 · tm2217670-4_4seq1.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,918

Underlying: Common Stock · 11,918 shares

Expires 2032-06-02

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 2, 2022 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.

SEC source: 0000899243-22-015186 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,309

Underlying: Common Stock · 24,309 shares

Expires 2032-04-18

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 18, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

SEC source: 0001104659-21-132482 · tm2131250-19_4seq1.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,918

Underlying: Common stock · 11,918 shares

Expires 2031-10-28

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of October 28, 2021 (the "Vesting Start Date") or (ii) the Issuer's next annual meeting of stockholders.

SEC source: 0000899243-21-025322 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2031-06-17

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 17, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

SEC source: 0001209191-21-030743 · doc4.xml · derivative · entry 3

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2031-03-03

F3 · derivative.exercise_date: 1/36th of the shares underlying this option will vest in equal monthly installments commencing one month after 11/15/2020.

SEC source: 0001209191-21-030743 · doc4.xml · derivative · entry 2

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2031-03-03

F2 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021.

SEC source: 0001209191-21-030743 · doc4.xml · nonDerivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: The shares will vest on 5/19/2021.

SEC source: 0000899243-20-016391 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 10, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through such vesting date.

SEC source: 0000899243-19-016226 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,580

Underlying: Common Stock · 15,580 shares

Expires 2029-06-06

F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 6, 2020 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through each such vesting date.

SEC source: 0000899243-18-008932 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,160

Underlying: Common Stock · 31,160 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019.

SEC source: 0001209191-17-059632 · doc4.xml · derivative · entry 5

Thistle Mary · CIK 0001317917 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2027-01-31

F5 · price: This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

F5 · derivative.exercise_date: This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

SEC source: 0001209191-17-059632 · doc4.xml · derivative · entry 4

Thistle Mary · CIK 0001317917 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,000 shares

Expires 2026-01-31

F4 · price: This stock option, which vests in 48 equal monthly installments beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

F4 · derivative.exercise_date: This stock option, which vests in 48 equal monthly installments beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

SEC source: 0001209191-17-059632 · doc4.xml · derivative · entry 3

Thistle Mary · CIK 0001317917 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,104 shares

Expires 2025-06-02

F3 · price: This stock option, which vested 2,494 shares on February 2, 2016, and vests in 41 equal monthly installments thereafter, beginning February 3, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

F3 · derivative.exercise_date: This stock option, which vested 2,494 shares on February 2, 2016, and vests in 41 equal monthly installments thereafter, beginning February 3, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

SEC source: 0001209191-17-059632 · doc4.xml · derivative · entry 2

Thistle Mary · CIK 0001317917 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 180,815 shares

Expires 2025-04-28

F2 · price: This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

F2 · derivative.exercise_date: This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

SEC source: 0001209191-17-059632 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,711 shares

Expires 2025-04-28

F1 · price: This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.

F1 · derivative.exercise_date: This stock option, which vests over four years beginning February 2, 2015, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.

SEC source: 0001209191-17-007636 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2027-01-31

F1 · derivative.exercise_date: This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017.